JP2011528720A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528720A5
JP2011528720A5 JP2011520147A JP2011520147A JP2011528720A5 JP 2011528720 A5 JP2011528720 A5 JP 2011528720A5 JP 2011520147 A JP2011520147 A JP 2011520147A JP 2011520147 A JP2011520147 A JP 2011520147A JP 2011528720 A5 JP2011528720 A5 JP 2011528720A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
substituted
administration
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011520147A
Other languages
English (en)
Japanese (ja)
Other versions
JP6049163B2 (ja
JP2011528720A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/051321 external-priority patent/WO2010011697A1/en
Publication of JP2011528720A publication Critical patent/JP2011528720A/ja
Publication of JP2011528720A5 publication Critical patent/JP2011528720A5/ja
Application granted granted Critical
Publication of JP6049163B2 publication Critical patent/JP6049163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011520147A 2008-07-21 2009-07-21 改善された治療上の特徴のための抗体の構造変異体 Active JP6049163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8239908P 2008-07-21 2008-07-21
US61/082,399 2008-07-21
PCT/US2009/051321 WO2010011697A1 (en) 2008-07-21 2009-07-21 Structural variants of antibodies for improved therapeutic characteristics

Publications (3)

Publication Number Publication Date
JP2011528720A JP2011528720A (ja) 2011-11-24
JP2011528720A5 true JP2011528720A5 (enExample) 2012-09-06
JP6049163B2 JP6049163B2 (ja) 2016-12-21

Family

ID=41570576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011520147A Active JP6049163B2 (ja) 2008-07-21 2009-07-21 改善された治療上の特徴のための抗体の構造変異体

Country Status (15)

Country Link
US (2) US7919273B2 (enExample)
EP (1) EP2318048B1 (enExample)
JP (1) JP6049163B2 (enExample)
KR (1) KR20110033233A (enExample)
CN (1) CN102159243B (enExample)
AU (1) AU2009274129B2 (enExample)
BR (1) BRPI0917204A2 (enExample)
CA (1) CA2731255C (enExample)
EA (1) EA201100228A1 (enExample)
IL (1) IL210307B (enExample)
MX (1) MX2011000891A (enExample)
NZ (1) NZ590330A (enExample)
UA (1) UA108735C2 (enExample)
WO (1) WO2010011697A1 (enExample)
ZA (1) ZA201100013B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
CA2766565A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2409989A1 (en) * 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
EP2663331A4 (en) * 2011-01-10 2015-07-15 Glaxosmithkline Intellectual Property Man Ltd NEW USES
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US9013184B2 (en) 2011-07-18 2015-04-21 Siemens Medical Solutions Usa, Inc. MR imaging system for automatically providing incidental findings
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CA2861428A1 (en) * 2012-01-19 2013-07-25 Therapeutic Proteins International, LLC Stabilization of the anti-cd20 antibody rituximab
US9447160B2 (en) 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
JP2015517511A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
CA2891764A1 (en) * 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
EP3666795A1 (en) * 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
US11576863B2 (en) 2013-03-15 2023-02-14 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
CA2910044A1 (en) * 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3313885A1 (en) * 2015-06-29 2018-05-02 H. Hoffnabb-La Roche Ag Type ii anti-cd20 antibody for use in organ transplantation
US10898522B2 (en) * 2015-08-19 2021-01-26 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
CN109154600A (zh) * 2016-06-16 2019-01-04 豪夫迈·罗氏有限公司 用于确定cdc诱导抗体的测定法和方法
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018071624A1 (en) * 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CN107384963A (zh) * 2017-07-31 2017-11-24 山东兴瑞生物科技有限公司 一种可控型cd20嵌合抗原受体修饰t细胞的制备方法及其应用
CN107693804A (zh) * 2017-10-10 2018-02-16 天津市肿瘤医院 一种靶向肿瘤乏氧微环境的超声微泡制备方法
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
WO2021041678A1 (en) * 2019-08-30 2021-03-04 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
WO2022042494A1 (zh) * 2020-08-27 2022-03-03 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CA3224171A1 (en) * 2021-07-01 2023-01-05 Rallybio Ipa, Llc Administration of anti-hpa-1a antibodies
US12441816B2 (en) 2021-09-21 2025-10-14 Qilu Puget Sound Biotherapeutics Corporation Heterodimeric Fc for making fusion proteins and bispecific antibodies
US20250019455A1 (en) * 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
WO1992007466A1 (en) 1990-11-05 1992-05-14 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5798554A (en) 1995-02-24 1998-08-25 Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno MOS-technology power device integrated structure and manufacturing process thereof
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
EP0954340B1 (en) 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
HK1048138B (zh) 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
JP2003528155A (ja) 2000-03-24 2003-09-24 カイロン コーポレイション Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP4745242B2 (ja) * 2003-05-20 2011-08-10 アプライド モレキュラー エボリューション，インコーポレイテッド Ｃｄ２０結合分子
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2005274905B2 (en) * 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
TW200630106A (en) * 2004-10-08 2006-09-01 Wyeth Corp Immunotherapy of autoimmune disorders
ZA200708857B (en) * 2005-04-22 2009-01-28 Genentech Inc Method for treating dementia or alzheimer's disease with a CD30 antibody
CA2631327C (en) * 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2011528720A5 (enExample)
JP2017501157A5 (enExample)
JP2017528462A5 (enExample)
JP2020503260A5 (enExample)
RU2664462C9 (ru) Комбинированная терапия с помощью антитела к CD19 и аналога пурина
JP2009518441A5 (enExample)
RU2010123363A (ru) Применения анти-cd40-антител
Ahmed et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up
US12194095B2 (en) Combinations and uses thereof
JP2017502667A5 (enExample)
JP2017507954A5 (enExample)
JP2016536314A5 (enExample)
RU2625222C2 (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
AU2024287178A1 (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
JP2018533569A5 (enExample)
RU2012120693A (ru) Модуляторы активатора фактора роста гепатоцитов
JP2013543869A5 (enExample)
WO2025085857A1 (en) Sirp antibodies for treatment of cancer
RU2013127115A (ru) Комбинированная терапия при в-клеточных лимфомах
EP3487506A1 (en) Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
HK40069168A (en) Combinations and uses thereof